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(1)is study aims to demonstrate the causal involvement of renin angiotensin system (RAS) and oxidative stress (OS) on vascular
in�ammation in an experimental model of metabolic syndrome (MS) achieved by fructose administration to spontaneously
hypertensive rats (FFHR) during 12 weeks. (2) Chronic treatment with candesartan (C) (10mg/kg per day for the last 6 weeks) or
4OH-Tempol (T) (10−3 mmol/L in drinking water for the last 6 weeks) reversed the increment in metabolic variables and systolic
blood pressure. In addition, chronic C treatment reverted cardiovascular remodeling but not T. (3) Furthermore, chronic treatment
with C was able to completely reverse the expression of NF-𝜅𝜅B and VCAM-1, but T only reduced the expression. C reduced the
expression of proatherogenic cytokines as CINC2, CINC3, VEGF, Leptin, TNF-alpha, and MCP-1 and also signi�cantly reduced
MIP-3, beta-NGF, and INF-gamma in vascular tissue in this experimental model. T was not able to substantially modify the
expression of these cytokines. (4) e data suggest the involvement of RAS in the expression of in�ammatory proteins at diﬀerent
vascular levels, allowing the creation of a microenvironment suitable for the creation, perpetuation, growth, and destabilization of
vascular injury.
1. Introduction
In�ammation is a ubiquitous pathological process which
is central to the development of multiple cardiovascular
diseases. Many vascular diseases such as atherosclerosis,
restenosis, and transplant vasculopathy are chronic, progres-
sive processes initiated and propagated by local in�ammation
of large- and medium-sized arteries [1].is in�ammation is
mediated by a variety of cell types including macrophages,
lymphocytes, endothelial cells (EC), and vascular smooth
muscle cells (VSMC). e multiple cell types which partici-
pate in vascular in�ammation have evolved to produce com-
mon cytokines and speci�c membrane receptors allowing
them to transmit their eﬀects into the cell, permitting these
diverse cell types to communicate by expression and recog-
nition of multiple pro- and anti-in�ammatory cytokines.
As such, cytokines and their receptors are the currency of
in�ammation, and represent attractive targets for therapeutic
modalities in numerous vascular in�ammatory disorders.
Synthesis and recognition of cytokines and receptors by
both vascular and in�ammatory cells allows bidirectional
communication between these two systems and demon-
strates that, under particular conditions, we can consider vas-
cular cells as an extended participant in the adaptive immune
response. Cytokines oen act in synergy with other cytokines
and frequently share receptor subunits which combine
into homodimers or heterodimers with receptors of other
cytokines. Cytokines can drive multiple, oen simultaneous,
cellular processes including mitogenesis, development, gene
expression, �brosis, and chemotaxis [2]. Proin�ammatory
cytokines most oen lead to activation of nuclear factor-
(NF-𝜅𝜅B) which acts as a “master switch” for transcription of
numerous genes, the expression of whichmay be appropriate,
as in host defense, or maladaptive, as in chronic vascular
disease [3–5].
e in�ammatory nature of atherosclerosis has prompted
broad investigation into vascular in�ammatory processes,
and consequently, proin�ammatory signalingmechanisms in
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the vascular wall have been well characterized [6–9]. Interest
has been placed on understanding the potentially protective
role of blocking renin-angiotensin system (RAS) and anti-
oxidative systems on vascular wall [10]. Such studies that
do exist place a strong emphasis on the role of angiotensin
and oxidative stress in the metabolic syndrome vascular
remodeling pathophysiology.
Spontaneously hypertensive rats (SHR) provide a model
of genetic hypertension that allows the study of essential
hypertension. e administration of carbohydrate-rich diets
to rats can induce insulin resistance, hyperinsulinemia, dys-
lipidemia, and moderate hypertension. Chronic fructose-fed
rats (FFR) provide a useful experimental model for study-
ing the interaction of the factors that shape the metabolic
syndrome. is combined model (FFHR) is representative
of hypertensive individuals who eat a modern Western diet
rich in re�ned sugars [11]. We postulate that this dual
experimental model could be appropriate for extrapolating
results to human pathology.
e hypothesis suggests that RAS and oxygen-free rad-
icals are actively involved in the activation of diﬀerent
molecular in�ammatory as cytokines, NF-𝜅𝜅B, and VCAM-
1 generating a microenvironment that allows cardiovascular
remodeling.
2. Methods
2.1. Animals and Experimental Design. All procedures were
performed according to institutional guidelines for animal
experimentation; protocol was submitted and approved by
the Institutional Committee for Laboratory Animal Use and
Care (CICUAL) of the School of Medicine-UNCuyo. irty-
day-old male Wistar Kyoto rats (WKY) and SHR were fed a
standard commercial chow diet ad libitum and housed in a
room under conditions of controlled temperature (20∘C) and
humidity, with a 12-hour light/dark cycle during a 12-week
experimental period. Candesartan (C) and 4OH-Tempol (T)
were administrated to respective groups during the last six
weeks.
(I) Control (W):WKY receiving food and drinkingwater
(DW) ad libitum.
(II) SHR: receiving food and DW ad libitum.
(III) Fructose-Fed Rats (FFR): WKY receiving 10% (w/v)
fructose (Parafarm, Buenos Aires, Argentina) solu-
tion in DW during all 12 weeks.
(IV) Fructose-fed Hypertensive Rats (FFHR): SHR receiv-
ing 10% (w/v) fructose solution in DW during all 12
weeks.
(V) FFHR+C: FFHR receiving 10mg/kg C by intrae-
sophageal administration.
(VI) FFHR+T: receiving 10−3MT in DW ad libitum.
At the end of the experimental period, rats were anes-
thetized with sodium pentobarbital (50mg/Kg ip), blood
samples were taken and arteries and organs were aseptically
excised for measurements.
2.2. Systolic Blood Pressure Measurement. Systolic blood
pressure (SBP) was monitored indirectly in conscious pre-
warmed slightly restrained rats by the tail-cuﬀ method and
recorded on a Grass Model 7 polygraph (Grass Instruments
Co., Quincy, MA, USA). e rats were trained in the
apparatus several times before measurement.
2.3. Biochemical Determinations
2.3.1. HOMA Index and Intraperitoneal Glucose Tolerance
Test. Fasting plasma insulin was assayed by ACS:180SE
automated chemiluminescence system (Bayer, Germany).
Plasma glucose levels were assayed using a commercial
colorimetric method (Wiener Lab., Argentina). Homeostasis
model assessment (HOMA) was used as an index to measure
the degree of insulin resistance; it was calculated using the fol-
lowing formula: [insulin (𝜇𝜇U/mL) × glucose (mmol/L)/22.5]
[12].
ree days before the end of the experimental period,
a glucose tolerance test (GTT) was performed. Rats fasted
overnight were slightly anesthetized with pentobarbital, and
glucose was administered (2 g/Kg ip). Blood samples were
taken by tail-bleeding at 0, 30, 60, and 90 minutes aer
injection to determine plasma glucose concentration. e
total area under the curve was calculated as mmol/L/90min.
2.3.2. Assessment of the �ipid Pro�le. At the end of the
experimental period blood samples were drawn from the
animals, aer fasting for 12 hours. Total plasma cholesterol,
HDL cholesterol and triglycerides were assessed using pho-
tocolorimetric enzymatic methods (Wiener Lab., Rosario,
Argentina). Data are expressed in mmol/L.
2.4. Oxidative Stress Determinations
2.4.1. Measurement of Plasma iobarbituric Acid-Reactive
Substances (TBARS). In order to demonstrate the eﬀect of
increased oxidative stress at the vascular level, plasma lipid
peroxidation was assessed by TBARS concentration. is
method was based on the reaction between plasma malondi-
aldehyde, a product of lipid peroxidation, and thiobarbituric
acid, as has been previously described [13]. No correction for
sample protein content was necessary because of the nature
of sample [14].
2.5. Measurement of Vascular NAD(P)H-Oxidase Activity.
e lucigenin-derived chemiluminescence assay was used to
determine NAD(P)H-oxidase activity in a segment of tho-
racic aorta, as previously described [13]. To assessNAD(P)H-
oxidase activity, NADPH (500 𝜇𝜇mol/L) was added and
chemiluminescence was immediately measured in a liquid
scintillation counter (LKB Wallac Model 1219 Rack-Beta
Scintillation Counter, Finland) set in the out-of-coincidence
mode. Time-adjusted and normalized-to-tissue-weight scin-
tillation counters were used for calculations. Measurements
were repeated in the absence and presence of dipheny-
lene iodinium (DPI) (10–6mol/L), which inhibits �avin-
containing enzymes, including NAD(P)H-oxidase [15, 16].
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2.6. eNOSActivity inHomogenates of Cardiac andArterial Tis-
sue. e activity of Ca2+/calmodulin-dependent endothelial
nitric oxide synthase, (eNOS) was measured in mesenteric
arteries homogenates and in le ventricle cardiac tissue,
by conversion of L-[3H]arginine into L-[3H]citruline. Val-
ues were corrected according to protein contents in the
homogenates (Bradford method) and to incubation time and
are expressed as dpm/mg protein/min.ematerial obtained
from each animal was processed independently [16].
2.7. Relative Heart Weight. In order to evaluate cardiac
hypertrophy, we measured relative heart weight (RHW).
Brie�y, heart was separated from the great vessels, dropped
into a buﬀered saline solution (PBS), blotted with tissue
paper to remove blood, and weighed. Total heart weight
was corrected according to the ratio between heart weight
(milligrams) and 100 grams of the total body weight before
killing.
2.8. Tissue Preservation. Tissue samples for histopathology
were processed as has been previously reported [17]. Samples
from all rats were used for these observations. Anesthetized
animals were brie�y perfused with PBS (29�mOsmol/Kg
H2O, pH 7.40, and 4∘C) to clear out the blood. Mesenteric
arteries were perfused in vivo with the same solution through
the mesenteric artery during 5min. For histological stud-
ies, arteries were also perfused with 4% paraformaldehyde
solution for 10min and �xed by paraﬃn. Five 𝜇𝜇m-thick
tissue slices were transversely cut across themesenteric tissue
on a microstate (Microm HM, Germany) and processed for
histological studies. Similar procedure was applied for heart
tissue preservation, by aortic retrograde perfusion.
2.9. Quantitative Histomorphometry to Determine Cardiac
Hypertrophy. Histomorphological analyses were conducted
on slices from the outer (free) wall of the le ventricle (LV) of
the heart. Estimations of cardiomyocyte area weremade from
sections stained with Masson trichrome solution. Areas with
transverse sections of myo�bers were selected. e contour
of the �bers was then drawn manually. Total myocardiocyte
area was expressed as square micrometer (𝜇𝜇m2).
2.10. Arterial Structure. Changes in the structure of arterial
walls were assessed by measuring the media layer in mesen-
teric arteries. Dissected mesenteric vascular beds were �xed
in 10% formaldehyde, dehydrated, embedded in paraﬃn, and
later cut in microtome.e slices were dyed and examined as
has been previously described [17]. Nontransverse sectioned
arteries were excluded from investigation. e lumen to
media ratio (i.e., internal diameter tomedial thickness) (M/L)
was then calculated. Fiy slices from each animal were
processed were analyzed to obtain an average value for each
rat. Average values were then used for �nal analysis.
2.11. SDS-PAGE and Immunoblot Analysis. Mesenteric tissue
was washed in PBS and proteins extracted in cold 20mM
Tris-HCl, pH 7.4, 150mM NaCl, 10% glycerol, 1% Triton
X-100, and a protease inhibitor mixture (P2714, Sigma).
Aer sonication for 15 s (3 times with 10-s intervals) and
extraction for 30min at 4∘C, sample extracts were clari�ed
by centrifugation at 14,000×g for 20min and used imme-
diately or stored at −20∘C. Proteins were separated on 10%
polyacrylamide slab gels and transferred to 0.22-𝜇𝜇m nitro-
cellulose membranes (GE, Germany). Nonspeci�c reactivity
was blocked by incubation for 1 h at room temperature in 5%
nonfat dry milk dissolved in washing buﬀer (PBS, pH 7.6,
and 0.2% Tween 20). Blots were incubated with anti-p65 and
anti-VCAM-1 antibodies (0.2 𝜇𝜇g/mL in blocking solution)
for 60min at room temperature. Horseradish peroxidase-
conjugated goat anti-rabbit-IgG and swine anti-goat-IgG dis-
solved in blocking buﬀer were used as secondary antibodies
(0.25 𝜇𝜇g/mL, 45min at room temperature). Excess �rst and
second antibodies were removed by washing 5 times for
5min in blocking solution. Detection was accomplished with
enhanced chemiluminescence system (ABC, Dako System)
and subsequent exposure to Kodak X-AR �lm (Eastman
Kodak) for 5–30 s.
2.12. Immunohistochemistry and Digital Confocal
Microscopy (IHC)
Determination of Transcription Factors (WB). Rabbit anti-
rat NF-𝜅𝜅B p65 subunit [Rel A], C-terminus antibody was
obtained from Millipore International Inc. (Amsterdam,
Netherlands) (AB1604b), and goat anti-rat VCAM-1 (C-19)
antibody was obtained from Santa Cruz Biotechnology Inc.
(Santa Cruz USA) (sc-1504). Tissue sections were cut at 3𝜇𝜇m
thickness from paraﬃn-embedded blocks. Deparaﬃnized
sections were used to determine in�ammatory response.
Tissue was permeabilized in 1% Triton X-100 for 15min,
rinsed well with PBS and blocked with sterile �ltered 10%
normal rabbit serum for 20min. All antibody solutions
were microfuged for 20min before use. e antibodies were
1 : 1000 diluted. Primary incubations lasted 1 hour at 21-
22∘C, followed by extensive washes in PBS with Triton X-
100, six times for 5min each. Secondary antibodies, anti-
rabbit IgG TR, and anti-goat IgG FITC (Sigma-Aldrich) were
diluted in PBS alone in compliance with the manufacturer’s
instructions.
Imageswere collectedwithNikonEZ-C1 3.00 soware on
aNikonDiaphot TMDmicroscope equipped for �uorescence
with a xenon lamp and �lter wheels (Sutter Instruments,
Novato, CA, USA), �uorescent �lters (Chroma, Brattleboro,
VT, USA), cooled charge-coupled device camera (Cooke,
Tonawanda, NY, USA), and stepper motor (Intelligent Imag-
ing Innovations, Inc., Denver, CO, USA). Multi�uor images
were merged, deconvolved, and renormalized using EZ-C1
3.00umbnailler soware.
2.13. Measurement of High-Sensitive C Reactive Protein (hs-
CRP) Concentration. Plasma HS-CRP concentrations were
measured using a turbidimetric assay (Bayer Advia 1650, AG
Leverkiusen). Data are expressed in mg/L.
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2.14. Cytokine Determination by “ChemiArray”. Cytokine
expression was assessed by ChemiArray system (rat antibody
arrays) (Chemicon International, USA): neutrophil chemo-
tactic cytokine 2 and 3 (CINC-2 and CINC-3), CX3CL1,
monocyte chemotactic protein-1 (MCP-1), macrophage
in�ammatory protein-3 alpha (MIP-3 alpha), nerve growth
factor beta (beta-NGF), tissue inhibitor ofmetalloproteinase-
1 (TIMP-1), vascular endothelial growth factor (VEGF),
granulocyte-macrophage colony-stimulating factor (GM-
CSF), interferon gamma (INF-𝛾𝛾), interleukin 1 alpha and beta
(IL-1𝛼𝛼, IL-1𝛽𝛽), interleukin 4, 6, and 10 (IL-4, IL-6, IL-10)
LIX, leptin, and tumor necrosis factor alpha (TNF-𝛼𝛼). We
proceeded, according to the manufacturer’s instructions, to
block nonspeci�c reactivity by incubation at room tempera-
ture for 1 h with a solution according to the instructive. e
membranes were incubated in solutions A and B for 60min
at room temperature. Horseradish peroxidase-conjugated
antibodies provided by the manufacturer were used. Excess
primary or secondary antibodywas removed or aer 5washes
of 5min with washing solution. Detection was performed
with chemiluminescence system and subsequent exposure
to Kodak X-AR �lm (Eastman Kodak) for 5�30 s. Citokines
were distributed in membranes according the map (Table 1).
2.15. Reagents. Unless otherwise noted, reagents were pur-
chased from Sigma Chemical Co., MO, USA.
2.16. Statistical and Data Analysis. Data are expressed as
mean ± SEM. e statistical signi�cance of data comparison
between all groups was assessed by one-way ANOVA fol-
lowed by Bonferroni post-test. A two-sided P value of less
than 0.05 was considered signi�cant.
3. Results
3.1. Biochemical Determinations. To categorize experimental
models we assessed metabolic pro�le of the diﬀerent groups.
Chronic administration of fructose induced several alter-
ations included in the cluster of risk factors that characterizes
MS.e comparison between HOMA index and areas under
the GTT curve evidenced that FFR and FFHR developed
glucose intolerance, as proven by the signi�cantly increased
HOMA index and area values compared to control rats
(Table 2).
On the other hand, the animals in FFR and FFHR
groups also showed signi�cant diﬀerences in the levels of
triglycerides and HDL-cholesterol when compared to their
controls (Table 2). SHR, FFR, and FFHR groups also showed
signi�cant diﬀerences in the levels of hs-CRP when com-
pared to WKY. FFHR group showed higher hs-CRP levels
than other groups (Table 2).
Chronic treatment with C signi�cantly reduced the
HOMA index and areas under the GTT curve; it also reduced
triglyceride levels andHDL-cholesterol, reversing the param-
eters that comprise the MS. Furthermore T partially but
signi�cantly reduced these variables. C signi�cantly reduced
the values of hsCRP, while T reduced them only partially. See
Table 2.
3.2. Systolic Blood Pressure Measurement. Table 2 also shows
the time-course of SBP changes along the experimental
period. By the sixth week, SBP of FFHR and SHR were
signi�cantly increased compared to the control group, and
there was also an increase in pressure in the FFR group, lower
but still signi�cant.
C normalized SBP to control values and T partially redu-
ced SBP values. C was more eﬀective and powerful in low-
ering the SBP. Probably the hypertensive state in this exper-
imental model, although it has a component of endothelial
dysfunction, should involve angiotensin 1 receptor (AT1R)
in the underlying mechanism.
3.3. Oxidative Stress Determinations. Vascular oxidative sta-
tus was assessed by measurement of the superoxide pro-
ducing enzymatic activity and its eﬀects on plasma lipid
peroxidation. Table 3 shows that NAD(P)H-oxidase activity
was signi�cantly higher in aortas fromFFHRwhen compared
to those from other groups. Plasma TBARS values are shown
in Table 3. Plasma TBARS concentration was signi�cantly
greater in FFR, SHR, and FFHR than in controls.
In addition, the arterial eNOS activity in the proposed
models was analyzed as shown in Table 3: FFHR signi�cantly
reduced their enzyme activity, contributing to decrease the
production and consequent bioavailability of nitric oxide
(NO).
ese results con�rm that these experimental models,
essentially FFHR, have a signi�cant superoxide production
and decreased NO bioavailability. T was eﬀective to reduce
superoxide production by reducing the activity of NAD(P)H-
oxidase and TBARS, and was also able to normalize eNOS
activity (Table 3). Furthermore C, probably by inhibiting the
activity of NAD(P)H-oxidase, was also able to achieve these
eﬀects, normalizing endothelial oxidative status (Table 3).
3.4. Quantitative Histomorphometry for Determining Cardiac
and Vascular Hypertrophy. e RHW and myocardiocyte
area were signi�cantly higher in FFR, SHR, and FFHR than
in control rats, demonstrating myocardial hypertrophy in
these experimental models (Table 3). e results of M/L
ratio calculated in mesenteric arteries are shown in Table 2.
FFHR always displayed a signi�cantly reduced M/L ratio
when compared to the corresponding arteries from WKY;
this result was also registered for FFR and SHR groups.
Chronic treatment with T signi�cantly reduced myocar-
dial hypertrophy and vascular remodeling, demonstrating
that oxidative stress, by activating diﬀerent mechanisms,
actively participates in the process of cardiovascular remod-
eling.
However, AT1R blockade by C was more eﬀective in
reducing these variables. e results demonstrate that intra-
cellular cascade post-AT1R activation is fundamental to both
cardiac and vascular remodeling processes, not only caused
by oxidative stress mechanisms, but also by grown factors.
3.5. Determination of Transcription Factors. As shown in
Table 4, some in�ammatory markers were evaluated in
mesenteric arteries, as well as the expression of NF-kappa B
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T 1: Metabolic and cardiovascular variables.
Variable WKY FFR SHR FFHR FFHR + C FFHR + T
Fasting glucose (mmol/L) 4.88 ± 0.1 6.44 ± 0.2∗ 5.0 ± 0.2 6.5 ± 0.2∗∧ 5.6 ± 0.1∗∗ 5.6 ± 0.1∗∗
Fasting triglycerides (mmol/L) 0.8 ± 0.0 1.8 ± 0.0∗# 0.9 ± 0.0 1.9 ± 0.1∗# 1.1 ± 0.2∗∗ 1.7 ± 0.1
HOMA index
(𝜇𝜇U/mL insulin ×mmol/L
glucose)/22.5
4.32 ± 0.1 10.93 ± 0.1∗# 7.2 ± 0.1∗ 14.1 ± 0.4∗#∧ 5.7 ± 0.5∗∗ 7.2 ± 0.1
Area under glucose tolerance test
curve
(mmol/L/90min)
881 ± 64 1392 ± 21∗# 1292 ± 31∗ 1839 ± 51∗#∧ 971 ± 54∗∗ 1200 ± 2.4∗
HDL-Cholesterol (mg/dL) 22.5 ± 0.7 12.2 ± 0.8∗# 19.3 ± 0.9∗ 13.6 ± 1.2∗#∧ 19.2 ± 1.4∗∗ 15.6 ± 2∗
High-sensitivity C reactive Protein
(mg/dL) 2.55 ± 0.1 3.5 ± 0.0 3.1 ± 0.1 4.5 ± 0.1
∗#∧ 2.01 ± 0.0∗∗ 4.0 ± 0.0∗
Systolic blood pressure (mmHg)
Baseline 105 ± 3 102 ± 1.0 103 ± 1 105 ± 3 105 ± 2 103 ± 1
6 weeks 113 ± 2.0 131 ± 3.0∗ 161 ± 3∗ 162 ± 2∗# 165 ± 2∗ 165 ± 2∗#
12 weeks 115 ± 1.3 136 ± 3.0∗ 177 ± 1∗# 181 ± 1∗#∧ 100 ± 2.5∗∗ 168 ± 1.1∧∗∗
e above values correspond to metabolic and cardiovascular variables.
Symbols indicate: ∗𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃𝑃 versus WKY; ∧𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃𝑃 versus SHR; #𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃 versus FFR; ∗∗versus FFHR.
T 2: Oxidative stress and morphometric variables.
Variable W FFR SHR FFHR FFHR + C FFHR + T
NAD(P)H oxidase activity
(counts/min/mg tissue) 40.5 ± 6 133 ± 5
∗ 160 ± 9.1∗# 297 ± 9.1∗#∧ 142 ± 9.1∗∧∗∗ 97 ± 2.1∗∧∗∗
Arterial eNOS activity
(dpm/mg/prot/min) 85.0 ± 2 60.1 ± 2.6
∗ 80.0 ± 2.1 56.4 ± 5.7∗#∧ 86.4 ± 1.1∗∗ 84.6 ± 1.1∗∗
TBARS (𝜇𝜇mol/L) 1 ± 0.1 2.2 ± 0.1∗ 1.69 ± 0.1∗ 2.8 ± 0.1∗#∧ 1.03 ± 0.6#∧∗∗ 0.73 ± 0.4#∧∗∗
Relative heart weight
(mg/100 g body weight) 225 ± 4 290 ± 4
∗ 330 ± 1.8∗# 400 ± 4∗#∧ 262 ± 4∗∗ 289 ± 4∗∗
Myocardiocyte area (𝜇𝜇m2) 1682 ± 69 2066 ± 57∗ 2222 ± 78∗# 3242 ± 55∗#∧ 1588 ± 55∗∗ 2188 ± 35∗∗
Media/Lumen ratio mesenteric
arteries 13.9 ± 0.3 10.2 ± 0.5
∗ 8.9 ± 0.6∗# 8.45 ± 0.2∗# 14.5 ± 5∗∗ 9.5 ± 5∗∗
e above values correspond to stress oxidative and morphometrics variables.
Symbols indicate: ∗𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃𝑃 versus WKY; ∧𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃𝑃 versus SHR; #𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃 versus FFR; ∗∗versus FFHR.
and VCAM-1, one of the posttranscriptional products that
actively participate in vascular in�ammation. Bothmolecules
were determined by IHC. e expression of these molecules
in the FFHR group increased signi�cantly compared to
control groups. In Table 4, right panel shows a representative
image of WB of these antibodies. Average optical density
signi�cantly increased in mesenteric artery homogenates
from FFHR and FFR groups compared to their controls. It
can be observed that the distribution of the 𝛽𝛽-actin marker is
similar for all groups.
Moreover, it can be seen in images obtained by IHC in
vascular wall of these experimental groups. FFHR shows a
large increase in NF-𝜅𝜅B expression at the level of EC and
VSMC, and also expressed VCAM-1 at subendothelial level.
C completely reduced activation and nuclear transloca-
tion of NF-𝜅𝜅B (p65 fraction) and VCAM-1 expression. On
the other hand, T was not able to signi�cantly reduce the
activation of NF-𝜅𝜅B and VCAM-1 expression, even though
the initial description of the activation of this molecule was
by ROS. is could be explained because in FFHR, nuclear
factor NF-𝜅𝜅B production was more important via superoxide
generated by AT1R activation. is �nding is very important
because blocking AT𝑃R at vascular level signi�cantly reduced
vascular in�ammation.ismay also be a determining factor
in the reduction of vascular remodeling, as previously shown.
3.6. Cytokine Determination by “ChemiArray System”. Aer
evaluation and analysis of vascular remodeling and in�am-
mation and increased hsCRP associated to the FFHR model
development, we decided to study the local expression of
cytokines (Figure 2). By using the previously described kit,
we were able to observe a signi�cant increase in several
cytokines in FFHR, including the followings: CINC2, CINC3,
VEGF, MIP-3, beta-NGF, VEGF, Leptin, TNF-alpha, INF-
gamma, and MCP-1 (Table 3). is �nding is the �rst
evidence of the presence of local in�ammation at vascu-
lar level in an experimental model of insulin resistance
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T 3: Cytokine release pro�les on diﬀerent experimental models.
Cytokinea Relative levelsb Array locationc Fold increase for control group (WKY)
d
SHR FFR FFHR FFHR + T FFHR + C
CINC-2 H E1-2 1.18 1.10 2.42 2.07 NC
CINC-3 H F1-2 1.34 1.30 2.74 2.00 NC
CNTF — G1-2 ∼ ∼ ∼ ∼ ∼
Fractalkine — H1-2 ∼ ∼ ∼ ∼ ∼
GM-CSF — A4-5 ∼ ∼ ∼ ∼ ∼
INF-𝛾𝛾 H B3-4 5.00 4.50 5.90 4.00 1.50
IL-1𝛼𝛼 — C3-4 ∼ ∼ ∼ ∼ ∼
IL-1𝛽𝛽 — D3-4 ∼ ∼ ∼ ∼ ∼
IL-4 — E3-4 ∼ ∼ ∼ ∼ ∼
IL-6 — F3-4 ∼ ∼ ∼ ∼ ∼
IL-10 — G3-4 ∼ ∼ ∼ ∼ ∼
LIX — H3-4 ∼ ∼ ∼ ∼ ∼
Leptin H A5-6 1.16 1.33 2.10 1.67 NC
MCP-1 H B5-6 1.25 NC 4.00 2.62 NC
MIP-3𝛼𝛼 H C5-6 1.16 1.33 3.91 2.50 1.25
𝛽𝛽-NGF H D5-6 2.40 2.40 3.50 2.93 NC
TIMP-1 H E5-6 2.60 1.52 2.50 1.90 NC
TNF-𝛼𝛼 H F5-6 3.19 1.10 3.35 2.80 1.30
VEGF H G5-6 2.50 NC 3.05 2.60 NC
a
Name of cytokine.
bRelative levels: —: undetectable; H: high; L: low.
cSee Figure 2 for the location of the duplicate spots in the matrix.
dWhen the control “∼” symbol was used to indicate an approximation of zero, the values indicate the fold increase versus Wistar Kyoto (WKY: control group).
NC: no change (less than or equal to fold diﬀerence from the level in WKY group).
T 4: ChemiArray Rat Lysate Cytokine Antibody Array I Map.
A B C D E F G H
1 Positive Positive Negative Negative CINC-2 CINC-3 CNTF Fractalkine
2 Positive Positive Negative Negative CINC-2 CINC-3 CNTF Fractalkine
3 GM-CSF INF-𝛾𝛾 IL-l𝛼𝛼 IL-l𝛽𝛽 IL-4 IL-6 IL-10 LIX
4 GM-CSF INF-𝛾𝛾 IL-l𝛼𝛼 IL-1𝛽𝛽 IL-4 IL-6 IL-10 LIX
5 Leptin MCP-1 MIP-3𝛼𝛼 𝛽𝛽-NGF TIMP-1 TNF-𝛼𝛼 VEGF Blank
6 Leptin MCP-1 MIP-3𝛼𝛼 𝛽𝛽-NGF TIMP-1 TNF-𝛼𝛼 VEGF Blank
7 Blank Blank Blank Blank Blank Blank Blank Positive
8 Blank Blank Blank Blank Blank Blank Blank Positive
Cytokines Names: Neutrophil chemotactic cytokine 2 and 3 (CINC-2 and CINC-3), ciliary neurotrophic factor (CNFT), monocyte chemotactic protein-1
(MCP-1), in�ammatory protein macrophage-3 alpha (MIP-3 alpha), nerve growth factor beta (beta-NGF), tissue inhibitor of metalloproteinase-1 (TIMP-1)
and vascular endothelial growth factor (VEGF), granulocyte colony stimulating factor, macrophage (GM-CSF), interferon gamma (INF-𝛾𝛾), interleukin 1 alpha
and beta (IL-1𝛼𝛼, IL-1𝛽𝛽), interleukin 4, 6, and 10 (IL-4, IL-6, IL-10), lipopolysaccharide-induced CXC chemokine (LIX or CXCL5), leptin, and tumor necrosis
factor alpha (TNF-𝛼𝛼).
such as FFHR. Others cytokines measurable by this kit,
especially interleukins, could not be evaluated because the
study was focused on the mesenteric tissue homogenate but
not on peripheral blood, where most of the interleukins
are found. �is result shows the signi�cant presence of
pro-atherogenic cytokines as CINC2, CINC3, VEGF, Lep-
tin, TNF-alpha, MCP-1, and TIMP-1, other with undeter-
mined signi�cance to vascular level even, as MIP-3 and
beta-NGF and other as INF-gamma with antiatherogenic
eﬀect.
Chronic treatment with T was ineﬀective in reversing the
expression of cytokines in the mesenteric vascular tree (Table
3).
Chronic treatment with C was able to reverse to control
values the expression of proatherogenic cytokines as CINC2,
CINC3, VEGF, Leptin, beta-NGF, TIMP-1, and MCP-1 and
also signi�cantly reduce MIP-3alpha, TNF-alpha, and INF-
gamma expression, demonstrating the important role played
by the RAS in vascular in�ammation in this experimental
model (Table 3).
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Nuclear p65 NF- B
Citoplasma p65 NF- B
100 kD VCAM-1
Control de carga
FFR FFRWKY WKY FFHRSHR FFHR + T FFHR + C
F 1: Cytoplasmatic and nuclear p-65 fraction of Nuclear Factor-𝜅𝜅B (NF-𝜅𝜅B) and Vascular cell adhesion protein 1 (VCAM-1) expression
in mesenteric arteries by western blot and Inmunohistochemistry. In up panel shows the western blot representative membrane in which
analyzed anti-VCAM-1-FITC and anti-p65-TRITC, the results were obtained by optic density of the bands revealed for each group. In top
panel shows microphotographs obtained by laser ICM 600x of mesenteric tissue.
ese results allow us to infer that the activation of
cytokines is mediated by a diﬀerent to redox-sensitive way
and AT1R receptor was actively involved in expression of
cytokines.
4. Discussion
is study was designed in order to test the hypothesis
that suggests the active involvement of RAS and oxidative
stress in the activation of diﬀerent in�ammatorymolecules as
cytokines, NF-𝜅𝜅B, and VCAM-1, generating a microenviron-
ment that allows cardiovascular remodeling (Figure 1). We
demonstrate the presence of humoral in�ammatory markers
at vascular level and transcription factors activation, also
allows establishing a cause-eﬀect relationship with the AT1R
activation.
To our knowledge, this is the �rst study showing anti-
in�ammatory eﬀect and inhibition of remodeling progres-
sion with a AT1R, candesartan, in an experimental model
of MS. AT1-R blocking are associated with reversion of
activation of vascular proin�ammatory mechanisms found
in metabolic syndrome models such as NF-𝜅𝜅B expression
or cytokine activation. Another important �nding is that
treatmentwith amimetic of superoxide dismutase has similar
anti-in�ammatory eﬀects to those found with C, although
weaker and was not eﬀective in reverting vascular remod-
eling. Moreover, superoxide blocking production did not
overcome protective eﬀects exerted by C.
e experimental model FFHR showed hypertension,
dyslipidemia, insulin resistance, vascular and cardiac remod-
eling, in�ammation demonstrated by increased hsCRP and
vascular in�ammation by increased the NF-𝜅𝜅B expres-
sion, VCAM-1, and proatherogenic cytokines. e increased
expression of VCAM-1, as discussed in the literature, is a
marker of vascular in�ammation, vascular permeability, and
endothelial dysfunction [18].
e in�ammatory process found in this experimental
model is not only circumscribed at vascular level but it is
also systemic, as demonstrated trough the increase in the
expression of hsCRP, which is synthesized in the liver in
response to increased IL-6. e experimental model showed
a very signi�cant increase of this protein [19, 20].
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F 2: Detection of cytokines onmembrane antibody arrays by chemiluminiscence. Each cytokine is represented by duplicate spots in the
following locations. See Table 4. Average net light intensity for each pair of cytokine spots detected on the basis of gray-scale levels using US
NIH Image soware ver. 1.66. Cytokines names: Neutrophil chemotactic cytokine 2 and 3 (CINC-2 and CINC-3), ciliary neurotrophic factor
(CNFT), monocyte chemotactic protein-1 (MCP-1), in�ammatory protein macrophage-3 alpha (MIP-3 alpha), nerve growth factor beta
(beta-NGF), tissue inhibitor ofmetalloproteinase-1 (TIMP-1) and vascular endothelial growth factor (VEGF), granulocyte colony stimulating
factor, macrophage (GM-CSF), interferon gamma (INF-𝛾𝛾), interleukin 1 alpha and beta (IL-1𝛼𝛼, IL-1𝛽𝛽), interleukin 4, 6, and 10 (IL-4, IL-6,
IL-10), lipopolysaccharide induced CXC chemokine (LIX or CXCL5), leptin, and tumor necrosis factor alpha (TNF-𝛼𝛼).
edata suggest the involvement of RAS in the expression
of in�ammatory proteins at diﬀerent vascular levels, allowing
the creation of a microenvironment suitable for the creation,
perpetuation, progression, and unstabilization of vascular
injury, be it a simple eutrophic vascular remodeling, or an
atherosclerotic lesion.
A likely explanation is the central role played by the
type 1 angiotensin II receptor. rough its intracellular p40
subunit, it is increasing NAD(P)H-oxidase activity, gener-
ating an increment of free radicals at both, extracellular
and intracellular levels, and activating diﬀerent cascades
of mediators such as PKC, JAK2, PI3K, FAK, and PLC.
ese intracellular signal are able to induce translocation
of the p65 subunit of NF-𝜅𝜅B and AP-1 activation [21]
with increased synthesis of cytokines, demonstrated in our
work. is activation can also be mediated by oxygen free
radicals without depending on the activation of the AT1R
but this answer seems to be inferior, with less recruitment of
cytokines. Another important point is close relationship with
insulin grown factor (IGF) by Src.is signal favoring growth
and remodeling of the extracellular matrix, stimulates pro-
duction of intracellular in�ammatory mediators such as NF-
𝜅𝜅B or AP-1, amplifying the vascular in�ammatory response
[22, 23].
is study demonstrates the central role of RAS in the
pathophysiology of metabolic syndrome. Moreover, it could
help to explain some of the �ndings obtained in large clinical
trials.
Our question on these results analysis was whether the
superoxide scavenger can restore the bioavailability of nitric
oxide or is there another mechanism? is question was
answered. Oxidative state is not the unique pathological
mechanism involved in the activation of proin�ammatory
molecules or vascular remodeling, it is also needed an intri-
catemessengers network, able to activate diﬀerent cascades to
enhance and extend endothelial responses to diﬀerent cells
involved in vascular injury process. RAS activates cascades
of growth, cell diﬀerentiation, and proin�ammatory mech-
anisms, acting as a key in the process of remodeling and
vascular injury.
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